170701-98-1

Basic information

• Product Name: (1-benzylpiperidin-2-yl)methanamine
• Synonyms: (1-benzylpiperidin-2-yl)methanamine;2-Aminomethyl-1-benzyl-piperidine
• CAS NO: 170701-98-1
• Molecular Formula: C₁₃H₂₀N₂
• Molecular Weight: 204.31
• Mol File: 170701-98-1.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (1-benzylpiperidin-2-yl)methanamine(CAS DataBase Reference)
• NIST Chemistry Reference: (1-benzylpiperidin-2-yl)methanamine(170701-98-1)
• EPA Substance Registry System: (1-benzylpiperidin-2-yl)methanamine(170701-98-1)

Safety Data

• Hazardous Substances Data: 170701-98-1(Hazardous Substances Data)

Usage

Description

(1-benzylpiperidin-2-yl)methanamine, commonly known as BZP, is a synthetic stimulant and entactogen with a chemical structure similar to amphetamines. It modulates the brain's neurotransmitter release, particularly serotonin and dopamine, leading to effects such as euphoria, increased energy, and heightened sensory perception.

Uses

Used in Recreational Drug Industry:
BZP is used as a recreational drug for its stimulant and entactogen effects, often taken alone or in combination with other substances. It has been marketed as a legal alternative to ecstasy due to its ability to induce feelings of euphoria and heightened sensory perception.
However, it is important to note that BZP is known to have potentially harmful side effects, such as increased heart rate, elevated blood pressure, and risk of seizures. Due to its potential for abuse and significant health risks, BZP has been classified as a controlled substance in many countries, and its use and distribution are regulated accordingly.

Upstream product

• 22990-77-8 C-piperidin-2-yl-methylamine 
• 100-39-0 benzyl bromide 
• 170701-86-7 2-(acetylamino)methyl-1-benzylpiperidine 

Relevant articles and documents

Design, synthesis, and in vitro evaluation of hydroxybenzimidazole-donepezil analogues as multitarget-directed ligands for the treatment of Alzheimer's disease

A series of multi-target-directed ligands (MTDLs), obtained by attachment of a hydroxyphenylbenzimidazole (BIM) unit to donepezil (DNP) active mimetic moiety (benzylpiperidine /-piperazine) was designed, synthesized, and evaluated as potential anti-Alzheimer's disease (AD) drugs in terms of biological activity (inhibition of acetylcholinesterase (AChE) and β-amyloid (Aβ) aggregation), metal chelation, and neuroprotection capacity. Among the DNP-BIM hybrids studied herein, the structural isomerization did not significantly improve the biological properties, while some substitutions, namely fluorine atom in each moiety or the methoxy group in the benzyl ring, evidenced higher cholinergic AChE activity. All the compounds are able to chelate Cu and Zn metal ions through their bidentate BIM moieties, but compound 5, containing a three-dentate chelating unit, is the strongest Cu(II) chelator. Concerning the viability on neuroblastoma cells, compounds 9 and 10 displayed the highest reduction of Aβ-induced cell toxicity. In silico calculations of some pharmacokinetic descriptors indicate that all the compounds but the nitro derivatives have good potential oral-bioavailability. Overall, it can be concluded that most of the studied DNP-BIM conjugates showed quite good anti-AD properties, therefore deserving to be considered in further studies with the aim of understanding and treating AD.